Navigation Links
Pacira Pharmaceuticals, Inc. Expands Development Collaborations for DepoFoam(R)
Date:4/15/2008

SAN DIEGO, April 15 /PRNewswire/ -- Pacira Pharmaceuticals, Inc. today announced a collaboration with Amylin Pharmaceuticals, Inc. for the development of sustained release injectable products based on the DepoFoam(R) technology platform from Pacira. The companies will work together to enhance the dosing profile for compounds within Amylin's early research and development pipeline. The goal of the collaboration is to develop multiple products based on sustained release, subcutaneous injection.

Dave Stack, President and CEO of Pacira stated, "In addition to our own lead development candidate, DepoBupivacaine(TM), we believe that delivery of Amylin's compounds using the DepoFoam(R) technology would create significant value for patient care, our partners, and Pacira."

"Pacira's DepoFoam(R) technology is an attractive delivery system and Amylin is excited to apply this technology to our peptide and protein therapeutics platform," said Christopher Rhodes, Ph.D., Executive Director, Pharmaceutical Sciences of Amylin. "This collaboration fits well with Amylin's research and development activities, which leverage our expertise in metabolism to develop potential therapies for diabetes and obesity."

Terms of the agreement are not disclosed at this time.

About Pacira

Pacira is an acute care specialty pharmaceutical company with a primary focus on developing Products which satisfy the needs of our customers in the institutional marketplace. The Company utilizes DepoFoam(R) delivery technology to cost-effectively improve patient care through enhanced dosing and administration profiles. Currently, the Company is developing DepoBupivacaine(TM) in phase III clinical studies for postsurgical pain. Revenues are generated from two approved products which are marketed by partners: DepoCyt(R) for lymphomatous meningitis and DepoDur(R) for post- surgical pain. Additional information about Pacira is available at http://www.pacira.com.

This press release contains forward looking statements, which involve risks and uncertainties within the meaning of the Private Securities Litigation Reform Act of 1995. There can be no assurance that actual results will not differ materially from the forward looking statements discussed in this press release. These forward looking statements include risks and uncertainties that current or future collaboration will prove to be commercially successful.


'/>"/>
SOURCE Pacira Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Laureate Pharma Announces Manufacturing Agreement With Alopexx Pharmaceuticals, LLC
2. Alseres Pharmaceuticals, Inc. Reports 2007 Financial Results and Provides Company Highlights
3. Aida Pharmaceuticals, Inc. Acquires High-Level Research Institute in the Peoples Republic of China
4. Jazz Pharmaceuticals, Inc. Announces Expansion of Senior Debt
5. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
6. Jazz Pharmaceuticals, Inc. Announces Webcast of March 13 Investor Meeting
7. Acura Pharmaceuticals, Inc. Reports 2007 4th Quarter and Annual Financial Results; Sets 2008 Expectations
8. Investor Alert from Cauley Bowman Carney & Williams, PLLC: Update on Proposed Acquisition of CollaGenex Pharmaceuticals, Inc. - CGPI
9. Strativa Pharmaceuticals, a Division of Par Pharmaceutical, Announces the Discontinuation of the Development Program for Pafuramidine
10. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results
11. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2007 Financial Results on Monday, February 25, at 8:30 A.M. EST
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative ... and patent-protected processes to develop and market advanced products ...  that it will present at the Needham Healthcare Conference ... H. "Pete" Petit, Chairman and CEO, Michael J. ... , EVP and Chief Commercialization Officer, and Mark ...
(Date:3/24/2017)... , March 24, 2017   Sienna Biopharmaceuticals, ... aesthetics company, today announced that Richard Peterson ... March 24.   Peterson, who brings more than ... John Smither , who is retiring at the end ... an advisory capacity. Peterson joins Sienna from Novan, Inc., ...
(Date:3/23/2017)... BETHESDA, Md. , March 23, 2017 /PRNewswire/ ... company developing DCVax® personalized immune therapies for solid ... on the $7.5 million financing it announced last ... Company sold to several institutional investors securities totaling ... $.26 per share, and 10,000,000 shares of Class ...
(Date:3/23/2017)... -- Kineta, Inc., a biotechnology company focused on ... today announced the discovery and characterization of several ... interferon response factor 3 (IRF3) via RIG-I like ... in a murine colon carcinoma mouse model.  Furthermore, ... regression to initial drug treatment were resistant to ...
Breaking Biology Technology:
(Date:3/6/2017)... March 6, 2017 Mintigo , ... today announced Predictive Sales Coach TM , its ... sales intelligence into Salesforce. This unique AI application ... sales organizations with deep knowledge of their customers ... intelligent engagement. Predictive Sales Coach extends Mintigo,s existing ...
(Date:3/2/2017)... Who risk to be deprived of its ... report: https://www.reportbuyer.com/product/4313699/ WILL APPLE AND SAMSUNG ... Fingerprint sensors using capacitive technology represent a fast growing ... forecasts an increase of 360% of the number of ... fingerprint sensor market between 2014 and 2017 (source : ...
(Date:2/28/2017)... 2017   Acuant , a leading provider of ... enhancements to new and core technologies building upon the ... mobile and desktop Acuant FRM TM facial recognition ... real time manual review of identity documents by accredited ... fastest and most accurate capture software to streamline workflows ...
Breaking Biology News(10 mins):